









HIPOPARA-RED, REAL LIFE EXPERIENCE IN 322 PATIENTS WITH HYPOPARATHYROIDISM  
 
Zanchetta María Belén1  ,Robbiani Damián1 , Oliveri Beatriz2 , Giacoia Evangelina3 , Frigeri Adriana4 , 
Kallsbrum Silvia5 , Salerni Helena5 , Lucas Sabrina6 , Diaz Adriana6 , Perez Betiana7, Pieroni Luisina4 , 
Arce Lange María Auxiliadora4 , Tormo Silvina3 , Kitaigrodsky Ariela7 , Galich Ana María.7  
 
1. IDIM, Instituto de Investigaciones Metabólicas. Universidad del Salvador. 2. Mautalen, Salud e 
Investigación. 3. Servicio de Endocrinología y Metabolismo Hospital Posadas. 4. Unidad de 
Endocrinología Hospital Dr. T. Alvarez. 5. Servicio de Endocrinología Hospital Carlos G Durand. 6. 
Sección Osteopatías Médicas, División Endocrinología de Clínicas José de San Martin-UBA. 7. Servicio 
de Endocrinología, Hospital Italiano de Buenos Aires. Buenos Aires, Argentina. 
Corresponding author’s contact information: 
María Belén Zanchetta, MD 
mbzanchetta@idim.com.ar 
Libertad 836, Buenos Aires, Argentina 
 
Disclosure summary: 
MBZ had received speaker honoraria from Shire/Takeda, Ultragenyx and Amgen. 
AMG had received speaker honoraria from Shire/Takeda.  
EG had received speaker honoraria from Takeda, Ultragenyx and Raffo. 
BO had received speaker honoraria from Shire/ Takeda. 
HS had received speaker honoraria from Amgen. 
The others authors declare that they have no conflict of interest concerning this paper. This study 
was done independently for Takeda and received no financial support to conduct it. 
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine 
Society. 
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-
nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the 





















Context: Hypoparathyroidism is a rare disease and as such, its natural history, long term 
complications and correct clinical management remain unclear.  
Objective: To describe the natural history and clinical characteristics of the disease.  
Design and setting: Topresent a retrospective observational analysis from seven specialized centers 
in Buenos Aires, Argentina. 
Patients: chronic hypoparathyroid patients followed up between 1985 and December 2018. 
 Main Outcome Measures: data on demographics, etiology, clinical complications, biochemical 
parameters, DXA values and treatment doses were collected. 
 Results: 322 subjects with chronic hypoparathyroidism were included, 85.7 % were female. Mean 
age was 55.2 ± 16.8 years and mean age at diagnosis was 43.8 ± 16.8. Prevalence of surgical 
hypoparathyroidism was 90.7 %, most common causes being thyroid carcinoma and benign thyroid 
disease. A history of hypocalcemia requiring hospitalization was present in 25.7 % and 4.3 % had a 
history of seizures. Overall, 40.9 % had reported at least one neuromuscular symptom. Renal 
insufficiency was present in 22.4 % and was significantly associated with age (p<0.0001). 
Hyperphosphatemia was present in 42 %. A history of severe hypocalcemia, paresthesias, tetany, 
ganglia calcifications, seizures and cataracts was significantly higher in nonsurgical patients. 
Conclusion: Although these patients were followed up by experienced physicians, clinical 
management was heterogeneous and probably insufficient to assess all the potential complications 
of this chronic disease. Almost 70 % of this group of patients met the experts´ indications for 
considering the use of rhPTH 1-84. Being aware of this fact is the first step to improve our medical 
management of this disease in the future. 
 






















Hypoparathyroidism is a rare disorder characterized by hypocalcemia and hyperphosphatemia due 
to absent or inadequate parathyroid hormone (PTH) secretion (1). The unintentional surgical 
damage of the parathyroid glands is the most common form, occurring in approximately 78 % of 
cases (1). Definitive postsurgical hypoparathyroidism is diagnosed when PTH production is 
insufficient to maintain normocalcemia six months after the intervention (2). Overall, the incidence 
of chronic hypoparathyroidism after neck surgery is < 2%, depending on the surgeon’s expertise (3). 
Nonsurgical hypoparathyroidism is attributable to autoimmune, genetic or idiopathic etiologies 
which typically become manifest in childhood (1). The estimated prevalence varies between 23- 30 
per million inhabitants in nonsurgical hypoparathyroidism and 220-250 per million inhabitants in 
surgical hypoparathyroidism  (4-6). 
As it is a rare disease, data on quality of life, long term risk of complications and correct clinical 
management have just started to emerge. What is best known is the spectrum of neuromuscular 
symptoms related to hypocalcemia: mainly paresthesia, cramps or tetany, but also seizures, 
bronchospasm, laryngospasm or cardiac rhythm disturbances (1). Fewer data are available regarding 
consequences in the renal, ophthalmic, and cardiovascular systems, fracture risk, infections and 
psychiatric conditions. The real prevalence of these complications is not available because 
systematic screening is scarce worldwide (7).  
Consequently, recent management guidelines stress the importance of a better clinical assessment 
of these patients (7). In addition to the routine biochemical monitoring of serum levels of calcium, 
phosphate and magnesium, some guidelines recommend a wider screening, as clinically indicated, 
including annual estimated glomerular filtration rate, renal imaging and 24-hr urinary calcium 
excretion. These screenings would be aimed at assessing renal insufficiency nephrocalcinosis and 
nephrolithiasis. Central nervous system imaging would evaluate basal ganglia calcifications- 





















 Inadequate PTH secretion causes failure to mobilize calcium from bone, reabsorb it from the distal 
nephron and stimulate renal 1α-hydroxylase activity, leading to hypocalcemia. Therapeutic tools 
include calcium and vitamin D supplements, active vitamin D (1, 25 (OH) vitamin D or calcitriol), 
analogues that require liver activation (1α hydroxyvitamin D: alfacalcidol and dihydrotachysterol) 
and thiazide diuretics (2). Higher calcium requirements may cause hypercalciuria and higher calcitriol 
doses increase the risk of hyperphosphatemia, so a delicate equilibrium is essential. Therefore, 
although there is little evidence available regarding how to best treat hypoparathyroidism, current 
general goals of management are: maintaining serum calcium levels in the lower part or slightly 
below the lower limit of the reference range, keeping serum phosphate and magnesium levels and 
24 hr urinary calcium excretion within range, and calcium–phosphate product below 55 mg2/dl2 (2,7-
9). A major challenge in hypoparathyroidism patients continues to be the effective therapeutic 
management of the disease in order to minimize the adverse effects of a life-long treatment.  
In 2015, replacement therapy with rhPTH (1-84) was first approved in the United States as a useful 
therapeutic option for hypoparathyroidism, restricted to those patients who are difficult to manage 
with conventional therapy (10). A group of experts recommend considering  its use based on these 
clinical criteria: inadequate control of the serum calcium concentration; very high oral 
calcium/vitamin D requirements (>2.5 g of calcium or >1.5 ug of active vitamin D or >3 ug of the 1- 
vitamin D analog), hypercalciuria, kidney stones, nephrocalcinosis or reduced creatinine clearance, 
hyperphosphatemia and/or calcium-phosphate product that exceeds 55 mg2/dl2, gastrointestinal 
tract disorder with malabsorption and reduced quality of life (2).  
This context of unmet needs and knowledge gaps motivated us to analyze and share our experience 
treating patients with this rare disease. Our primary endpoint was to describe the natural history 
and clinical characteristics of a group of patients with hypoparathyroidism from seven referral bone 
centers in Argentina. The secondary endpoint was to describe differences between surgical and 
nonsurgical HP patients and our third endpoint, to analyze the number of patients on inadequate 




















Material and methods 
Patients 
A retrospective observational analysis of chronic hypoparathyroidism patients from seven 
specialized centers (Hipopara-Red) from Buenos Aires, Argentina, was carried out. To be included, 
subjects should have had concurrent measurement of albumin-corrected or ionized serum calcium 
below the lower limits of the normal range and low or undetectable levels of PTH, on at least two 
occasions separated by 2 weeks. A duration ≥ 6 months of hypocalcemia was considered for 
inclusion criteria in surgical hypoparathyroidism. Patients with pseudo hypoparathyroidism were 
excluded. Each center collected requested data from all patients fulfilling the inclusion criteria from 
their historic database and its analysis was carried out by a centralized institution. Data of 
demographics, age at diagnosis, disease duration (period between diagnosis and last visit) and 
etiology were recorded. Clinical manifestations or complications were registered regarding 
hypocalcemia requiring hospitalization, neuromuscular manifestations (paresthesias, tetany, muscle 
spasms or pain and seizures), kidney ultrasound positive findings (stones or nephrocalcinosis), renal 
insufficiency (defined by creatinine clearance below 60ml/min), basal ganglia calcification, detailed 
fragility fracture history and cataracts. All the above clinical manifestations or complications were 
considered positive and included in the analysis, if present at least once during follow- up. Most 
recent biochemical parameters available in medical records included serum calcium (mg/dl), ionized 
calcium (mg/dl), serum phosphorus (mg/dl), calcium-phosphate product (mg2/dl2), PTH (pg/ml), 
serum 25-hydroxyvitamin D (ng/ml), 24-hr-urine calcium and serum magnesium (mg/dl). In most 
patients, baseline parameters were not available for analysis. Most recent DXA values and treatment 
regimens (type and doses) were also collected. According to the WHO criteria, osteoporosis was 
defined as a BMD that lies 2.5 standard deviations or more below the average value for young 
healthy women (a T-score of <-2.5 SD). In women prior to menopause and in males younger than 




















Differences between surgical and nonsurgical hypoparathyroidism regarding demographics, clinical 
manifestations, biochemical parameters, DXA values and treatment were analyzed. 
 The study was conducted according to the Helsinki Declaration and was approved by a local ethics 
committee. Each participant was identified by a number to ensure confidentiality.  
Data analysis 
Data were expressed as mean ± SD and the Shapiro-Wilk and Bartlett tests were used to assess 
normality and equal variances respectively. The Student’s t test or Mann-Whitney test was used as 
appropriate to compare surgical and nonsurgical groups. Differences were considered significant if p 
< 0.05. Statistical analyses were performed with STATISTIX 7.0 Copyright ©1995, 2000 Analytical 
software (Statsoft). The association between each complication and possible associated factors was 




A total of 322 subjects with chronic hypoparathyroidism were included, 276 (85.7 %) were female 
and 46 (14.3 %) male (female/male ratio 6:1). The mean age at the last visit was 55.2 ± 16.8 years; 
only three subjects were younger than 18 years of age (0.9 %). The mean age at diagnosis was 43.8 ± 
16.8 years; disease duration (median time between diagnosis and last visit) was 10.9 ± 9.9 years 
(Table 1). This database included all subjects followed up between 1985 and December 2018 in 
Buenos Aires, capital city of Argentina. Last follow-up visit date ranged from December 2002 to 
November 2018. 
Etiology 
The majority of patients had surgical hypoparathyroidism (90.7 %, n=292; 258 female and 34 male) 
mainly due to thyroid carcinoma (45.6 %), benign thyroid adenoma (37.3 %), parathyroidectomy (5.6 
%) and other neck surgeries (2.2 %). Benign thyroid adenoma implied benign thyroid disease 




















hypoparathyroidism represented the remaining 9.3 % (n=30, 18 female and 12 male): idiopathic (5 
%), autoimmune (2.8 %) and Di George (1.5 %). See figure. 
In a sub- analysis of patients who had undergone thyroid surgery of benign and malignant etiologies, 
we noticed a significant trend over the years. Before 2010, 49.6 % of our patients became 
hypoparathyroid following a surgery to remove a benign thyroid adenoma. After 2010, 
hypoparathyroidism secondary to surgery for benign thyroid disease went down to 37.2 % (p= 
0.0330).  
Clinical manifestations and complications 
 Paresthesias were found in 31.3 %, tetany in 14.2 %, muscle spasms in 13.3 %, and muscle pain in 
6.8 %;  40.9 % reported at least one neuromuscular symptom. 
 A history of hypocalcemia requiring hospitalization was present in 25.7 % (n=83) and fourteen 
patients (4.3 %) had a history of seizures. These two events were related; seizures were significantly 
associated with hospitalization for hypocalcemia (p=0.017). Also, seizures were positively associated 
with hyperphosphatemia, elevated calcium-phosphate product and higher doses of calcium 
supplementation (p= 0.019, 0.020 and < 0.0001, respectively). Basal ganglia calcifications were 
present in 5/14 patients with a history of seizures, although only 8/14 had been screened using 
central nervous system imaging. (Table1). Out of all the participants (n=322), basal ganglia 
calcifications were present in 23 patients. Although it is worth noting that the screening  rate was 
very low, only 59/322 had had undergone nervous system image screening.  Patients with basal 
ganglia calcifications without seizures did not have any other neurological problems, at least 
reported in this data base, except for paresthesias, muscle spasms or tetany, which as a whole, were  
present in 83.3%.   
Kidney assessment by renal ultrasound was performed in 41.9 % (135/322) and 15.5 % (21/135) had 
positive findings (kidney stones (n=15); nephrocalcinosis (n=6)). Creatinine clearance calculation 




















patients (22.4 %). Renal insufficiency was significantly associated with age (p < 0.0001): 2/50 (4 %) in 
patients younger than 39, 17/106 (16 %) in patients between 40 and 59 years of age, 25/95 (26. 3 %) 
in patients between 60 and 79 and 18/26 (69.2 %) in patients older than 80. Patients older than 60 
years of age had 2.9-fold more risk than those younger than 60 to have creatinine clearance below 
60ml/min (Odds ratio: 2.918; 95 % confidence interval: 1.617 to 5.263) 
Regarding fracture history, only nontraumatic fractures were included and were present in 4.9 % of 
our group: a total of 17 fractures (4 hip, 1 fibula, 2 humerus, 1 rib, 3 vertebrae and 6 wrists) in 14 
patients, mean age 71.2 years, range 23 to 94 years. All fractured patients were female, except for a 
23-year old male with Di George Syndrome diagnosed with celiac disease after bilateral hip fracture. 
Apart from this young man, the other youngest patient was a 50-year-old woman with a history of 
hyperparathyroidism and premature ovarian failure who fractured her wrist. All the other fractured 
patients were older than 60 years old. As regards hypoparathyroidism etiology, 78.5 % (11/14) were 
postsurgical, one had Di George and two were idiopathic. Disease duration ranged between 7 and 44 
years. Vertebral fractures (N=3) were clinical and confirmed by X-ray, associated with osteopenia or 
osteoporosis, and present in patients older than 80. 
Only 3.4 % (n=11) reported a history of cataracts, mean age was 64±19.5 (22-87 years), with a mean 
disease duration of 20.2±11.9 years (5-38 years). Mean phosphorus level was 4.7±0.8   mg/dl (upper 
limit of the normal range). In this group, 8/11 patients had a surgical etiology (mean age 78) and 
three nonsurgical (mean age 43). The youngest woman with cataracts was 22 years old, had a five-
year autoimmune hypoparathyroidism, hyperphosphatemia, basal ganglia calcifications and a history 
of multiple hospitalizations for hypocalcemia. 
Biochemical parameters  
Data for serum calcium were available in 99.3 % and mean calcium level was 8.4 ± 0.8mg/dl; 46 % 
were below the lower limit, 53.6 % within normal range and only one patient had hypercalcemia 
(table 2). Plasma phosphate values were available in 95.4 %; only one patient was below the lower 




















product (>55 mg2/dl2) was present in 1.2 %.  Mean serum PTH levels were low (13.4 ± 10.8 pg/ml) 
and clearly inadequate for serum calcium values. Serum 25-hydroxyvitamin D levels were available in 
46 %, 50.7 % were higher than 30 ng/ml, 30.4 % between 20 and 30 ng/ml and 18.9 % under 20 
ng/ml. Urinary 24-hr calcium excretion was available in 58.4 % and 49.4 % of those screened had 
values above the gender reference range.  
Serum magnesium levels were available in 80.1 % (n =247) and were lower than the reference range 
in 24.3 % of patients. Only one patient had values above the normal range. The rest (75 %) were 
within the reference range but in the medium or lower tertile of normal range. Remarkably, half of 
the patients with serum magnesium levels in the lower tertile were receiving supplements. 
DXA values  
Lumbar spine and hip DXA assessment was performed in 38 % (123/322) of the patients. Mean 
lumbar spine T-score was -0.3 ± 1.9, mean femoral neck T-score was -0.3 ± 1.5 and mean total hip T- 
score -0.2 ± 1.3. There were not significant differences in T-score or Z-scores values between 
postsurgical or nonsurgical patients (data not shown). Although mean values were within the normal 
range, 48/123 (39 %) had osteopenia and 16/123 (13 %) had osteoporosis. 
Treatment 
The decision on treatment election was made by the patient´s endocrinologist. Most patients were 
receiving calcium supplements (mean dose 2019 ± 1426 mg/day, expressed as elemental calcium) 
plus calcitriol (mean dose 0.498 ± 0.279 ug/day) and 22.9 % were receiving diuretics 
(hydrochlorothiazide (16 %), indapamide (3.7 %)) (table 2). More than half (54.3 %) were receiving 
vitamin D supplementation. 
Fourteen patients (4.3 %) were receiving PTH supplementation, 13 female and one male; median age 
was 49.57 (18- 88 years) and median time since diagnosis was 9 years. Thirteen were receiving     
rhPTH 1-34 and one rhPTH 1-84. These patients had a history of frequent intravenous calcium 
administration and episodes of life-threatening severe hypocalcemia. Thirteen were postsurgical 




















(0,51ug/day). It is important to clarify that these off-label rhPTH 1-34 treatments were started 
before rhPTH 1-84 was available and approved for hypoparathyroidism. 
Differences between surgical and nonsurgical HP patients  
Nonsurgical hypoparathyroidism subjects were younger and diagnosed at a younger age; 
female/male ratio was more balanced: 60 % were women (table 1). A history of severe 
hypocalcemia, paresthesias, tetany and muscle spasms was significantly more frequent in 
nonsurgical patients. Ganglia calcifications, seizures and cataracts were significantly higher. There 
were no differences regarding renal complications, biochemical parameters, DXA values or 
treatment characteristics (Table 1 and 2). 
Candidates who met experts’ indications for considering the use of rhPTH 1-84  
According to the international guidelines, 210 of our patients met experts’ indications for 
considering the use of rhPTH 1-84 . If we add the fourteen that were already receiving it, the number 
rises to 69.5 % (n=224) of our group  (2) (Table 3). Hyperphosphatemia would be the indication for 
the majority (n=124), daily oral calcium requirements exceeding 2.5 g of calcium in 74, and only one 
because of >1.5 µg of active vitamin D. Inadequate control of the serum calcium concentration was 
the reason why fourteen patients were already under rhPTH 1-34 or rhPTH 1-84. In the remaining 
cases, the patients presented hypercalciuria, kidney stones, nephrocalcinosis, or reduced eGFR. (See 
detailed numbers in table 3). Quality of life was not evaluated so it could not be used as an 
indication criterion. (or could not be considered within the indication criteria) 
Discussion 
In this observational retrospective cross-sectional study, we described the natural history of 322 
subjects with hypoparathyroidism. We found a higher prevalence of postsurgical etiology (90.7 %) 
compared with the prevalence described in the literature (67 -78 %) (1, 2, 6). This could be 
attributed to the fact that our centers mainly treat adults, so we do not usually see pediatric patients 




















Most of our patients were premenopausal women, whose diagnosis was made after a thyroid 
surgery, what is consistent with the prevalence of thyroid nodular disease. Regrettably, almost 40 % 
suffered this life-long condition after a surgery for a benign thyroid disease. The extents of the 
surgery, central compartment node dissection and reoperation have been described as risk factors 
for developing hypoparathyroidism (12). We had no data on the type of surgical procedure but, 
fortunately, after 2010 we observed a significant decrease in the number of patients becoming 
hypoparathyroid after a surgery for benign thyroid disease.  
History of severe hypocalcemia requiring hospitalization was present in one out of four; and less 
severe hypocalcemia was responsible for at least one neuromuscular symptom, this being reported 
in 40 %. The prevalence of seizures was similar to that described in the literature (4- 8 %) and it was 
clearly more prevalent in nonsurgical patients (3). 
Concern has been raised regarding renal impairment as higher risk of kidney stones, 
nephrocalcinosis, renal insufficiency and even dialysis have been described (4). Kidney stones or 
nephrocalcinosis were found only in 15.5 % of our group, probably because less than half of our 
patients had had a renal ultrasound performed. A high prevalence of nephrocalcinosis (12 to 57 %) 
and a hazard ratio for developing kidney stones of 4.82 (95 % CI: 2.00–11.64) was reported in 
patients with hypoparathyroidism who were treated with calcium and activated vitamin D 
(4,13).Renal insufficiency, defined by creatinine clearance below 60ml/min, was present in 22.4 % of 
our patients and it was significantly associated with age, ranging from 4 % in younger than 39- year-
olds to 69.2 % in patients older than 80. This prevalence is higher than expected for our general 
population; in a study done on 88,500 blood and urine samples in Buenos Aires, the authors 
reported a prevalence of 12 % (14).  Impaired renal function has been associated with age, duration 
of the disease and relative time with hypercalcemia (15). Two-thirds of subjects included in an early 
intervention trial had decreased creatinine clearance values at baseline, and 40 % had verified renal 
calcinosis (16). In a US cohort, 41 % of patients had an eGFR < 60 ml/min/1.73 m2, which was 




















the hazard ratios for renal insufficiency were 3 (95 % CI: 1.73–5.55) and 6 (95 % CI: 2.45–14.75) for 
patients with surgical and nonsurgical hypoparathyroidism, respectively, compared with 
age-matched controls (4, 17) 
Data on fracture risk among patients with this disorder vary. In some postsurgical hypoparathyroid 
cohorts, patients may have a decreased risk of fracture in the upper extremities, whereas others 
show an increased risk of vertebral fractures despite having normal or increased bone mineral 
density (18-21) Nontraumatic fractures were present in 5 % of our group and almost all had 
happened in aged postmenopausal women. Although there are no published data on the general 
incidence of fragility fractures in our country, prevalence of asymptomatic vertebral fractures in 
Argentinian women aged 50 was estimated in 16.19 % in the LAVOS´S study (22).  
In our group, 42 % had serum phosphate levels above the reference range. Underbjerg et al. 
recommend that serum phosphate in this population should be kept in the lower part of the 
reference interval, because higher phosphate levels are associated with increased mortality and risk 
of infections (17). Unfortunately, in our patients, lowering serum phosphate seems to be one of the 
most challenging tasks. 
In Argentina, we tend to favor calcium over active vitamin D use: mean calcium elemental 
requirements were around 2000 mg/day and calcitriol 0.5 ug/day. This perspective is similar to the 
US experience and different from the European, which focuses more on the 1-alpha analogue of 
vitamin D than on supplemental calcium. Fourteen patients were receiving PTH supplementation: 
thirteen with rhPTH 1-34 and one with rhPTH 1-84. These patients had previously had more frequent 
hospitalizations, more severe hypocalcemia, higher serum phosphate and calcium urinary excretions 
and higher calcium and calcitriol requirements than a control group of patients receiving standard 
treatment (23). With PTH supplementation, their serum calcium levels improved and calcium and 
calcitriol requirements decreased and became similar to those of the conventionally treated group.   
As expected and previously reported, nonsurgical hypoparathyroidism subjects were younger and 




















Overall, they seem to have more complications, especially those related to hypocalcemia such as 
neuromuscular symptoms, cataracts, basal ganglia calcifications and seizures (5). Underberj et al. 
found that these patients had a significantly increased risk of renal insufficiency ([HR] 6.01), 
cardiovascular diseases (HR 1.91), neuropsychiatric complications (HR 2.45), infections (HR 1.94) and 
fractures at the upper extremities compared with a control group (5).  
According to the experts’ indications, 210 of our patients might be eligible for the use of rhPTH, 
although it is not yet commercially available in Argentina (2). However, these indications are not 
strict evidence-based recommendations but rather guidance to consider treatment with f rhPTH 1-
84.  We were surprised and worried about the high percentage of patients with inadequate control, 
especially patients with hyperphosphatemia and renal complications. This high number might 
partially be explained by the significant percentage of patients older than 60 years of age and even 
older than 80 with renal insufficiency. 
We are aware that due to the retrospective design of our study, the prevalence of acute and chronic 
complications is probably underdiagnosed in our patients. Less than half of our patients met the 
screening recommendations for renal ultrasound, 24-hr urine calcium excretion and central nervous 
system imaging assessment, which probably underestimated the prevalence of basal ganglia 
calcifications, nephrocalcinosis, hypercalciuria and kidney stones. Also, we only recorded self-
reported cataracts. We were not able to evaluate quality of life, fatigue, lack of concentration, 
depression, and other neuropsychiatric issues. Other limitations of this study are that the 
participating centers were almost exclusively for adults, which exaggerates surgical etiology, and the 
lack of genetic testing for the diagnosis of nonsurgical cases. Moreover, all centers were from the 
capital city, Buenos Aires, and it is uncertain whether these data can be extrapolated to the whole 
Argentinian population. Patients in our cohort were evaluated at reference centers and thus, they 
might have been more severely affected with a higher rate of complications than the overall 
population (referral bias).  Finally, the results of laboratory values over a time span and from 




















That being said, our results were generally consistent with peer‐reviewed reports. The main 
strengths of this study are the large number of patients included, the long follow-up period and the 
complete biochemical profile. In addition, according to our knowledge, this is the first study on 
hypoparathyroidism in Argentina and Latin America. 
As a conclusion, analyzing our experience, we have learned several lessons. Despite being followed 
up by experienced physicians, clinical management and monitoring were heterogeneous and 
probably insufficient to assess all the potential complications. Hyperphosphatemia was present in a 
high proportion of our patients and more than half might have been eligible to receive treatment 
with rhPTH 1-84 .  Being aware of our current management of this rare disease is the first step to 
improve our clinical approach in the future. Longitudinal prospective studies including the whole 
country are necessary to permit a better understanding of the clinical manifestations, short- and 
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Tables and figures 
Table 1. Demographic data and clinical characteristics of the whole group, surgical and nonsurgical 
subgroups 




Non-surgical (n=30) p 
Demographics n (%)    
Age (years) 54.3 ± 16.8 55.4 ± 16.1 43.3 ± 18.9 0.0003 
Female 276 (85.7 %) 258 (88.3 %) 18 (60 %) 0.0002 
Age at diagnosis 43.8 ± 16.8 45 ± 15.9 31.4 ± 20.5 <0.01 
Disease duration (years) 10.9 ± 9.9 10.7 ± 10 12.5 ± 9.5 0.25 
Clinical Manifestations (%)     
Severe hypocalcemia 83 (25.7) 68 (23.2) 15 (50) 0.003 
Paresthesias 101 (31.3) 84 (28.7) 17 (56.6) 0.003 
Tetany 46 (14.2) 35 (12) 11 (36.6) 0.001 
Muscle spams 43 (13.3) 35 (12) 8 (26.6) 0.042 
Muscle pain 22 (6.8) 19 (6.5) 3 (10) 0.444 
Seizures 14 (4.3) 7 (2.3) 7 (23.3) <0.0001 
eGFR <60 [n (%)] 62 (22.4) 58 (23) 4 (16) 0.42 
Lithiasis/nephrocalcinosis 21/135 (15.5) 19/117 (16.2) 2/18 (11.1) 0.738 
Basal ganglia calcification 23/59 (38.9) 14/46 (30.4) 9/13 (69.2) 0.021 
Fracture history 14 (4.3) 11 (3.8) 3 (10) 0.131 
Cataracts 11 (3.4) 8 (2.7) 3 (10) 0.072 
 




































Nonsurgical (n=30) p 
      
Calcium (8.5-10.5 mg/dl) 8.4 ± 0.8 8.4 ± 0.8 8.4 ± 0.9 0.51
&
 
Ionized calcium (4.1-5.2 mg/dl) 4.2 ± 0.5 4.3 ± 0.5 4.1 ± 0.6 0.17
&
 
Albumin (3.2-4.8 g/l) 4.1 ± 0.4 4.1 ± 0.4 4.3 ± 0.4 0.14
&
 
Phosphorus (2.5-5 mg/dl) 4.7 ± 0.9 4.7 ± 0.9 4.9 ± 1.0 0.12
&
 
PTH (10-65 pg/ml) 13.4 ± 10.8 13.5 ± 10.9 11.7 ± 9.6 0.47
&
 
25-hydroxyvitamin D (30ng/ml) 34.9 ± 13.2 34.3 ± 13.1 42.6 ± 13.5 0.029
&
 
Magnesium (1.9-2.5 mg/dl) 1.9 ± 0.2 1.9 ± 0.2 1.9 ± 0.2 0.66
&
 
Urine calcium (220 mg/24hr) 201.5 ± 131.9 198.5 ± 134.4 228.2 ± 105.6 0.16
&
 
Hypercalciuria (%) 98/174 (56.3) 87/156 (55.7) 11/18 (61.1) 0.803
  





)  76.0 ± 24.8 74.8 ± 23.5 88.2 ± 34.2 0.07 
     
Treatment (doses)     
Calcium (mg/day) 2019 ± 1426 2033 ± 1447 1876 ± 1232 0.67 
Calcitriol (ug/day) 0.498 ± 0.279 0.491 ± 0.275 0.566 ± 0.321 0.26 




















Thiazides (mg/day) 30.8 ± 21.4 32.7 ± 22.0 16.2 ± 5.9 0.17 
Vitamin D (thousand IU/week) 
 
28.1 ± 22  27.6 ± 22 33.3 ± 26 0.37 
 
Abbreviations:  PTH: parathormone; eGFR: estimated glomerular filtration rate;    
#Unequal variances.  & Non-parametric distribution.
  Two-Sample Proportion Test. We provide t and z-scores 
for all patients (n=123), although T-score (<-2.5 SD) was used in postmenopausal women and men older than 
50 and Z-score in women prior to menopause and in males younger than age 50 (≤ -2.0) to define osteoporosis 
or low bone mass, respectively. Vitamin D was both ergo or cholecalciferol. Patients receiving rhPTH 1-84 or 





















Table 3. Indications for considering the use of rhPTH 1-84 in our patients (2). Several patients 
fulfilled more than one of the criteria. The 14 patients already with rhPTH 1-84 or rh PTH 1-34 were 
the ones with inadequate control of the plasma calcium concentration. 
Indications for Considering the Use of rhPTH Number of patients 
Inadequate control of the plasma calcium concentration 14     (4.34%) 
Oral calcium that exceeds 2.5 g of calcium  
 ≥1.5 ug of calcitriol  
74     (22.9%) 




Reduced  clearance (≤60 mL/min) 
98    (30.43%) 
15    (4.65%) 
6     (1.86%) 
62    (19.25%) 
Hyperphosphatemia and/or calcium-phosphate product  
Exceeding 55 mg2/dL2 (4.4 mmol2/L2) 
124 (38.55) 






















Figure legend:  
Etiology in 322 patients with hypoparathyroidism. Thyroid adenoma implies benign thyroid disease 
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